Company

Our mission is to change the way medicine is practised by reducing several routine and important diagnostic screening tests to a simple blood draw using the power of the 5-hydroxymethylcytosine (5hmC) epigenetic modification.

Our Timeline

Founded in 2012 by Professor Sir Shankar Balasubramanian, co-inventor of Solexa sequencing which underpins the market-leading Illumina® sequencing technology, and Dr Bobby Yerramilli-Rao, Cambridge Epigenetix is pioneering the epigenetics revolution.

2009
2017
2009
  1. Seminal 5hmC publications released

    Professor Anjana Rao’s team at Harvard Medical School and Dr Nathaniel Heintz’s group at Rockefeller University independently publish on a new epigenetic DNA modification - 5-hydroxymethylcytosine (5hmC).

  2. oxBS technique invented

    The technique of oxBS is invented by Professor Sir Shankar Balasubramanian’s group at the University of Cambridge, allowing, for the first time, single-base resolution analysis of 5-hydroxymethylcytosine (5hmC) and 5-methylcytosine (5mC).

  3. Cambridge Epigenetix founded

    Cambridge Epigenetix founded to commercialise oxBS, providing access to the wider epigenetics research community.

  4. TrueMethyl oxBS kits launched

    TrueMethyl oxBS kits launched providing reproducible and accurate analysis of 5hmC and 5mC.

  5. £5.5M Series A funding round

    Cambridge Epigenetics raises $5.5M in Series A funding to further develop and commercialise tools for epigenetic analysis.

  6. $21M Series B funding round

    Cambridge Epigenetics raises $21M in Series B funding to support further expansion of the business and investment in initial epigenetic biomarker discovery programmes utilising our proprietary platforms.

  7. New TrueMethyl Kit launched

    TrueMethyl Whole Genome kit launched to further streamline epigenetics discoveries.

  8. High-profile SAB established

    Cambridge Epigenetix establishes Scientific Advisory Board comprising experts within oncology, liquid biopsy and ageing to further drive the company’s transition towards epigenetic biomarker discovery.

  9. Fundamental methylation IP licensed

    Cambridge Epigenetix licenses fundamental DNA methylation IP from Boston Children’s Hospital providing exclusive access to best-in-class techniques and freedom to commercialise novel epigenetic assays.

  10. HMCP: A disruptive new discovery platform

    The company develops HMCP, a highly sensitive, high-throughput platform for high-resolution analysis of 5hmC, enabling cost-effective biomarker discovery.

  11. 5hmC diagnostic pilot study

    Pilot studies using HMCP allow stratification of case vs control samples for a range of cancer types from liquid biopsy (LQB) samples - allowing the development of minimally invasive epigenetic-based assays for early cancer detection.

  12. New purpose-built facilities

    Rapid growth prompts move to new purpose-built facilities allowing further expansion of biomarker discovery and validation capabilities.

  13. TrueMethyl licensed to NuGEN

    Cambridge Epigenetix licenses TrueMethyl oxBS technology to NuGen Technologies Inc, allowing the company to fully focus on epigenetic biomarker discovery and diagnostic assay development programmes.

Our Team

Dr. Jason Mellad

Chief Executive Officer

Hayden Jeffreys

Chief Operating Officer

Dr. Joanne Mason

Vice President Biomarker Discovery

Dr. Vitali Proutski

Vice President of Informatics

Deborah Tonge

Director of Finance

Maria Ferguson

Director of Human Resources

Professor Sir Shankar Balasubramanian FRS

Co-Founder and Chair of the SAB

Dr. Bobby Yerramilli-Rao

Co-Founder/Co-Chairman

Tom Hulme

General Partner, GV

Roelof F. Botha

Partner, Sequoia Capital

Dr. Martin Murphy

CEO, Syncona Partners LLP

Timothy J Rink, MD, ScD

Co-Chairman

Somu Subramaniam

Co-Founder and Managing Partner, New Science Ventures

Professor Wolf Reik

Head of the Epigenetics Programme, Babraham Institute

Professor Jay Shendure

Professor of Genome Sciences, University of Washington

Professor Anjana Rao

Head of the Division of Signalling and Gene Expression, La Jolla Institute

Professor Mark Dawson

Group Leader of the Cancer Epigenetics Laboratory, Peter MacCallum Cancer Centre

Together, we will make disease optional, not inevitable

Join UsCareers